ACAD / Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours more_horizontal

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associa more_horizontal

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever. more_horizontal

September hasn't been overly kind to growth stocks. This latest bout of volatility, however, may have created some compelling buying opportunities. more_horizontal

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions more_horizontal

Acadia Pharmaceuticals (NASDAQ: ACAD) stock price did well on Wednesday even as American equities retreated. The biotech stock jumped to a high of $26 more_horizontal

Acadia Pharmaceuticals' gains recently disappeared despite the strong launch of Daybue. Poor market conditions are to blame, especially the poor biote more_horizontal

Acadia Pharmaceuticals shows fiscal resilience with a shift to net positive income, buoyed by Daybue's strong Q2 debut and increased Nuplazid sales. D more_horizontal